Published in Cancer Immunol Res on October 30, 2014
Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature (2016) 1.63
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med (2015) 1.58
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol (2015) 0.82
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol (2016) 0.78
Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF(V600E) melanoma. Oncoimmunology (2015) 0.76
Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Front Pharmacol (2016) 0.75
Cytotoxic T-cell cytokines put cancer under arrest. Cancer Immunol Res (2014) 0.75
A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. Clin Cancer Res (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J (1999) 10.82
Melanoma biology and new targeted therapy. Nature (2007) 10.71
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer (2001) 5.58
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science (1996) 3.70
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A (1996) 3.62
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol (1997) 2.71
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell (2011) 2.17
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol (2011) 2.15
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res (2012) 2.14
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 2.02
Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis (2006) 1.85
Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 1.81
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res (2014) 1.79
Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 1.73
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70
Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med (2014) 1.60
Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 1.51
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res (2014) 1.10
Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut (2001) 1.07
Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci U S A (2013) 0.95
Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell Melanoma Res (2013) 0.89
Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. BMC Genomics (2012) 0.88
Chimeric antigen receptor-modified T cells in CLL. N Engl J Med (2011) 0.86
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med (2015) 1.58
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clin Cancer Res (2014) 1.46
Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metab (2015) 1.05